Direct oral anticoagulants and digestive bleeding: therapeutic management and preventive measures
Open Access
- 17 April 2017
- journal article
- review article
- Published by SAGE Publications in Therapeutic Advances in Gastroenterology
- Vol. 10 (6) , 495-505
Abstract
The use of direct oral anticoagulants (DOACs) was an important step forward in the management of atrial fibrillation and venous thromboembolism (VTE). The DOACs, anti-IIa for dabigatran and anti-Xa for rivaroxaban, apixaban and edoxaban, all have a rapid onset of action and a short half life. There is no need for routine hemostasis testing for treatment monitoring of a DOAC. Compared with vitamin K antagonists (VKAs), DOACs may increase the risk of gastrointestinal bleeding (relative risk 1.25). Withholding the DOAC treatment, evaluating the time of the last intake and estimating the patient’s renal function are the first steps in the management of gastrointestinal bleeding. For patients without impaired renal function, achieving low coagulation takes around 24 h after the last intake of a DOAC. The use of DOAC antagonists will be helpful in controlling bleeding in the most severe and urgent situations. Idarucizumab is available for clinical use for dabigatran and andexanet is currently being reviewed by drug agencies for rivaroxaban, apixaban and edoxaban. It is important to assess the bleeding risk associated with the planned procedure, and the patient’s renal function before withholding DOAC therapy for a scheduled intervention. It is mandatory to strengthen the local hemostasis strategies in DOAC-treated patients undergoing a therapeutic endoscopic procedure. Resuming or not resuming anticoagulation with a DOAC after bleeding or a risky procedure depends on the thrombotic and bleeding risk as well as the procedure involved. This discussion should always involve the cardiologist and decisions should be taken by a pluridisciplinary team.Keywords
Funding Information
- Bayer HealthCare
This publication has 30 references indexed in Scilit:
- Andexanet Alfa for Acute Major Bleeding Associated with Factor Xa InhibitorsNew England Journal of Medicine, 2016
- Comparison of the Novel Oral Anticoagulants Apixaban, Dabigatran, Edoxaban, and Rivaroxaban in the Initial and Long-Term Treatment and Prevention of Venous Thromboembolism: Systematic Review and Network Meta-AnalysisPLOS ONE, 2015
- XANTUS: a real-world, prospective, observational study of patients treated with rivaroxaban for stroke prevention in atrial fibrillationEuropean Heart Journal, 2015
- Prevention of Dabigatran-Related Gastrointestinal Bleeding With Gastroprotective Agents: A Population-Based StudyGastroenterology, 2015
- Idarucizumab for Dabigatran ReversalNew England Journal of Medicine, 2015
- Incidence of hospital admissions due to adverse drug reactions in France: the EMIR studyFundamental & Clinical Pharmacology, 2014
- Rates, management, and outcome of rivaroxaban bleeding in daily care: results from the Dresden NOAC registryBlood, 2014
- Recommendations for the emergency management of complications associated with the new direct oral anticoagulants (DOACs), apixaban, dabigatran and rivaroxabanClinical Research in Cardiology, 2013
- Reversing Dabigatran in Life-Threatening Bleeding Occurring During Cardiac Ablation With Factor Eight Inhibitor Bypassing ActivityCritical Care Medicine, 2013
- Gastrointestinal bleeding with the new oral anticoagulants – defining the issues and the management strategiesThrombosis and Haemostasis, 2013